Open | - |
Close | - |
Volume / Avg. | 0 / 273.011K |
Day Range | - - - |
52 Wk Range | 2.860 - 7.755 |
Market Cap | $201.488M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 39 |
Short Interest | % |
Days to Cover | 25.46 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Verrica Pharmaceuticals (NASDAQ: VRCA) through any online brokerage.
Other companies in Verrica Pharmaceuticals’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Zevra Therapeutics (NASDAQ:ZVRA), Third Harmonic Bio (NASDAQ:THRD), Xeris Biopharma Holdings (NASDAQ:XERS) and Alimera Sciences (NASDAQ:ALIM).
The latest price target for Verrica Pharmaceuticals (NASDAQ: VRCA) was reported by Needham on Friday, March 1, 2024. The analyst firm set a price target for 8.00 expecting VRCA to rise to within 12 months (a possible 68.42% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Verrica Pharmaceuticals (NASDAQ: VRCA) is $4.75 last updated March 18, 2024 at 4:01 PM EDT.
There are no upcoming dividends for Verrica Pharmaceuticals.
Verrica Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Verrica Pharmaceuticals.
Verrica Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.